Search results
Results From The WOW.Com Content Network
Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. [3] Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 ...
Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Neonatal alloimmune thrombocytopenia. Neonatal alloimmune thrombocytopenia ( NAITP, NAIT, NATP or NAT) is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus ' or newborn's platelets. A low platelet count increases the risk of bleeding in the fetus and newborn.
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Shares of Novartis (NVS) soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon (ACL) for $12.9 billion. Novartis had been trying to gain ...
Newborn screening ( NBS) is a public health program of screening in infants shortly after birth for conditions that are treatable, but not clinically evident in the newborn period. The goal is to identify infants at risk for these conditions early enough to confirm the diagnosis and provide intervention that will alter the clinical course of ...
The Neonatal Behavioral Assessment Scale ( NBAS ), also known as the Brazelton Neonatal Assessment Scale ( BNAS ), [1] was developed in 1973 by T. Berry Brazelton and his colleagues. [2] This test purports to provide an index of a newborn's abilities, and is usually given to an infant somewhere between the age of 3 days to 4 weeks old. [1]